Study Title
12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
Purpose
To compare the efficacy of relamorelin with placebo in participants with Diabetic Gastroparesis with respect to a composite of the following core signs and symptoms of: *Nausea *Abdominal pain *Postprandial fullness *Bloating
Eligibility
Study Process
Trial Details
Investigator:
IRB:
Copernicus
IRB Number:
Trial Type:
Drug
Sponsor:
Allergan
Contact Information: